Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period
You may also be interested in...
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo further delays plans for a generic version of Reckitt Benckiser's Mucinex, saying the product it once touted as a 2010 highlight may not emerge even during the firm's fiscal 2011
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo further delays plans for a generic version of Reckitt Benckiser's Mucinex, saying the product it once touted as a 2010 highlight may not emerge even during the firm's fiscal 2011
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo further delays plans for a generic version of Reckitt Benckiser's Mucinex, saying the product it once touted as a 2010 highlight may not emerge even during the firm's fiscal 2011